Comparison · NCT02173379-794b32b9
Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Absorb BVS vs XIENCE: Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF). Trial comparisons, record NCT02173379-794b32b9. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02173379-794b32b9
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.166 | 0.146 | 0.188 | wilson | |
| Risk in group 2 | 0.125 | 0.108 | 0.145 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0404 | 0.0124 | 0.0685 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.32 | 1.09 | 1.61 | log | |
| Odds ratio, group 1 over group 2 | 1.39 | 1.1 | 1.74 | log | |
| Number needed to treat, for one more participant with the outcome on Absorb BVS than on XIENCE | 24.7 | 14.6 | 80.9 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Absorb BVS | Subjects receiving Absorb Bioresorbable Vascular Scaffold (BVS) System, and the Absorb GT1™ BVS System | 200 | 1,206 | OG000 |
| Group 2 | XIENCE | Subjects receiving XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (outside of the US only) or XIENCE ProX (outside of the US only) | 153 | 1,220 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Experienced Cardiac Death/TV-MI/ID-TLR (TLF)
- Description
- Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR).
- Time frame
- 4 years
- Population
- ITT population. The number of participants analyzed includes subjects who had available follow up data at that time frame.
Source ClinicalTrials.gov
Trial
- Title
- Absorb IV Randomized Controlled Trial
- NCT number
- NCT02173379
- Phases
- NA
- Conditions
- Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
- Interventions
- Absorb BVS, XIENCE
- Lead sponsor
- Abbott Medical Devices
- Results first posted
- 2018-07-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02173379?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02173379-794b32b9